Rina-S

Phase 3Small molecule

Genmab

Rina-S is one of 30 small molecule programs targeting Gastrointestinal Cancers. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal CancersRecruiting

Non-Small Cell Lung Cancer (NSCLC)Recruiting

Epithelial Ovarian CancerRecruiting

Platinum Sensitive Ovarian CancerRecruiting

Gastrointestinal CancersPhase 2

Recruiting

Non-Small Cell Lung Cancer (NSCLC)Phase 2

Recruiting

Epithelial Ovarian CancerPreclinical

Recruiting

Platinum Sensitive Ovarian CancerPhase 3

Recruiting

Competition

Competitive Landscape

32 competitors in Non-Small Cell Lung Cancer (NSCLC)

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

4 2

Trodelvy

Gilead

Phase 3

3 3

DATROWAY

Daiichi Sankyo

Phase 3

1 4

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

6 5

Paraplatin

AAvyxa

Phase 3

4 6

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

3 7

Rina-S

Genmab

Phase 3

1 8

Xospata

Astellas

Phase 1

1 9

Rasonque

Revolution Medicines

Phase 1

2 10

Pemetrexed/carboplatin

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Epithelial Ovarian Cancer

NCT05579366

Q2 2028

Phase 3Active, not recruiting

Platinum-Resistant Ovarian Cancer

NCT06619236

Q4 2028

Phase 2Recruiting

Gastrointestinal Cancers

NCT07539311

Phase 2Recruiting

Non-Small Cell Lung Cancer (NSCLC)

NCT07288177

Phase 3Recruiting

Platinum-Resistant Ovarian Cancer

NCT07604766

Q4 2029

Phase 3Recruiting

Endometrial Cancer

NCT07166094

Clinical

Trials by Indication[1]

Platinum-resistant Ovarian Cancer2 trials

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT06619236·530 enrolled

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Recruiting· Genmab logo

Genmab·Phase 3·NCT07604766·82 enrolled

Gastrointestinal Cancers1 trial

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Recruiting· Genmab logo

Genmab·Phase 2·NCT07539311·160 enrolled

Ovarian Cancer1 trial

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Recruiting· Genmab logo

Genmab·Phase 3·NCT07225270·544 enrolled

Endometrial Cancer1 trial

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Recruiting· Genmab logo

Genmab·Phase 3·NCT07166094·660 enrolled

Platinum Sensitive Ovarian Cancer1 trial

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Recruiting· Genmab logo

Genmab·Phase 3·NCT07564141·688 enrolled

2 more indications

Epithelial Ovarian Cancer1 trial

Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors

Recruiting· Genmab logo

Genmab·Preclinical·NCT05579366·884 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

Recruiting· Genmab logo

Genmab·Phase 2·NCT07288177·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Rina-S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rina-S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rina-S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Genmab

Rina-S

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Platinum-resistant Ovarian Cancer2 trials

Gastrointestinal Cancers1 trial

Ovarian Cancer1 trial

Endometrial Cancer1 trial

Platinum Sensitive Ovarian Cancer1 trial

Epithelial Ovarian Cancer1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

References

Drug Info

Quick Facts

Related News